Back to search results
NCT06215547

Medtronic Enterra II Neurostimulator

UNKNOWN
NAAges 18–70InterventionalTreatment
Methodist Health System
~500 participants
Updated 2024-11-20 on ClinicalTrials.gov
What's tested:Enterra HDE

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treating Self Reported Nausea and Vomiting using Enterra II during procedure
Measured over Up to 30 days

Conditions

Gastroparesis

Explore related trials

GastroparesisNauseaVomiting

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Sachin Kukreja, MD · PRINCIPAL_INVESTIGATOR · Methodist Heath System

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.

Exclusion

Organ transplant
Organic obstruction
Pseudo-obstruction
Prior gastric surgery
Scleroderma
Amyloidosis
History of seizures
Peritoneal or unstable dialysis
Chemical dependency
Pregnancy
Primary eating or swallowing disorders
Psychogenic vomiting
Implanted electronic medical devices
Age \< 18 or \> 70 years

What this trial measures

  • Treating Self Reported Nausea and Vomiting using Enterra II during procedureUp to 30 days

    Using Enterra II system to prevent self reported Nausea and vomiting during a procedure